

Receipt date: 07/13/2009

PTO/SB/08a (01-09)

Approved for use through 02/28/2009. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>				<b>Complete if Known</b>	
				Application Number	10/511,980
				Filing Date	4/7/2005
				First Named Inventor	Amalfitano et al.
				Art Unit	1633
				Examiner Name	Fereydoun Ghotb Sajjadi
				Attorney Docket Number	180/151 PCT/US
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature	/Fereydoun Sajjadi/	Date Considered	07/29/2009
-----------------------	---------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/511,980
				Filing Date	4/7/2005
				First Named Inventor	Amalfitano et al.
				Art Unit	1633
Examiner Name	Fereydoun Ghotb Sajjadi				
Sheet	2	of	2	Attorney Docket Number	180/151 PCT/US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
/F.G.S./	8	Allen et al., "Improved Adeno-Associated Virus Vector Production with Transfection of a Single Helper Adenovirus Gene, E4orf6," Mol. Ther., Vol. 1, pgs. 88-95 (2000).		
	9	Amalfitano et al., "Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted," J. Virol., Vol. 72, pgs. 926-933 (1998).		
	10	Amalfitano et al., "Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid- $\alpha$ -glucosidase," PNAS, Vol. 96, pgs. 8861-8866 (1999).		
	11	Gao et al., "High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle Virus," Hum. Gene Ther., Vol. 9, pgs. 2353-2362 (1998).		
	12	Gao et al., "Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap," Mol. Ther., Vol. 5, pgs. 644-649 (2002).		
	13	He et al., "A simplified system for generating recombinant adenoviruses," PNAS, Vol. 95, pgs. 2509-2514 (1998).		
	14	Hodges et al., "Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein," J. Gene Med., Vol. 2, pgs. 250-259 (2000).		
	15	Lieber et al., "Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo," J. Virol., Vol. 70, pgs. 8944-8960 (1996).		
	16	Liu et al., "Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus," Gene Ther., Vol. 6, pgs. 293-299 (1999).		
	17	Muzyczka, N., "Use of adeno-associated virus as a general transduction vector for mammalian cells," Current Topics in Microbiology and Immunology, Vol. 158, pgs. 97-129 (1992).		
	18	Sun et al., "Packaging of an AAV Vector Encoding Human Acid $\alpha$ -Glucosidase for Gene Therapy in Glycogen Storage Disease Type II with a Modified Hybrid Adenovirus-AAV Vector," Mol. Ther., Vol. 7, pgs. 467-477 (2003).		
	19	Van Hove et al., "High-level production of recombinant human lysosomal acid $\alpha$ -glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease," PNAS, Vol. 93, pgs. 65-70 (1996).		
	20	Weitzman et al., "Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers," J. Virol., Vol. 70, No. 3, pgs. 1845-1854 (1996).		
	21	Zhang et al., "Recombinant adenovirus expressing adeno-associated virus cap and rep proteins supports production of high-titer recombinant adeno-associated virus," Gene Ther., Vol. 8, pgs. 704-712 (2001).		

Examiner Signature	/Fereydoun Sajjadi/	Date Considered	07/29/2009
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.